Status:
NOT_YET_RECRUITING
Mesenchymal Stem Cells for Treatment of Poor Graft Function After Allogeneic Hematopoietic Stem Cell Transplantation
Lead Sponsor:
ShiCang Yu
Collaborating Sponsors:
Xinqiao Hospital of Chongqing
Conditions:
MSC
Eligibility:
All Genders
18-60 years
Phase:
PHASE4
Brief Summary
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an effective approach for treating both benign and malignant blood disorders. It primarily involves high-dose chemotherapy to eliminat...
Eligibility Criteria
Inclusion
- Screening patients for allogeneic hematopoietic stem cell transplantation;
- No gender limit, age ≥18 years old and ≤60 years old;
- KPS score \>60 points, expected survival period \>3 months;
- Those without serious functional damage to important organs throughout the body;
- The patient has no other contraindications to hematopoietic stem cell transplantation
- Voluntary test and informed consent.
Exclusion
- Have severe heart, kidney or liver dysfunction;
- Those combined with other malignant tumors need treatment;
- There are clinical symptoms of brain dysfunction or severe mental illness and the inability to understand or follow the research protocol;
- Patients who cannot be guaranteed to complete the necessary treatment plan and follow-up observation;
- Patients with severe acute allergic reactions;
- Clinically uncontrolled active infection;
- Patients who are participating in other clinical trials;
- Researchers believe that the subject is not suitable for clinical trials for other reasons.
Key Trial Info
Start Date :
January 1 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
November 1 2028
Estimated Enrollment :
68 Patients enrolled
Trial Details
Trial ID
NCT06171906
Start Date
January 1 2024
End Date
November 1 2028
Last Update
December 15 2023
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Xinqiao Hospital
Chongqing, Shapingba District, China, 410000
2
Second Affiliated Hospital, Army Medical University, PLA
Chongqing, China